Overall, as reported previously, the GALAD score is superior in distinguishing between HCC and cirrhosis when compared with traditional biomarkers, such as AFP, DCP (PIVKA-II), and AFP-L3. This evidence concerns the gene ACE and hepatocellular carcinoma.